The opinion rejects granting conditional marketing authorization to AB Science’s masitinib as an oral add-on treatment for ALS in the EU.

CHMP upheld earlier opinions that Translarna is not of significant benefit to DMD due to nonsense mutations; European ...

Soligenix, Inc. (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, ...

NanoViricides, Inc. (NYSE Amer.: NNVC ) (the “Company”), a clinical stage global leader in broad-spectrum antiviral nanomedicines, today announces that Anil R. Diwan, Ph.D., the Company’s President ...

First major treatment advance in nearly 25 years; Gliomas target individuals in the prime of life, often in their 30s and 40s ...

Nido Biosciences (Nido Bio), a clinical stage company developing precision medicines for debilitating neurological diseases, ...

Samsung Biologics landed a $1.24 billion contract manufacturing deal with an Asian pharmaceutical giant, shattering its ...

Healthcare decision-makers are facing significant challenges that will intensify in the coming years as they work to address ...

BeiGene (BGNE) announced that the Committee for Medicinal Products for Human Use – CHMP – of the European Medicines Agency issued ...

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

The fully-owned Intas Pharmaceuticals subsidiary Accord Healthcare has announced that the Committee for Medicinal Products ...

Novartis NVS announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (EMA ...